Table: Fuji Pharmaceutical -2023/24 parent forecast
2023/24 6-month parent forecast
Table: Fuji Pharmaceutical -2022/23 parent results
Table: Fuji Pharmaceutical -2022/23 group results
Mithra jumps as Fuji Pharma filed Estelle for dysmenorrhea
Brief: Mithra To Receive EUR 2.5 Million Milestone Payment From Fuji Pharma
Brief: Vistagen And Fuji Enter Exclusive Negotiation Agreement For A Potential License To Develop And Commercialize Vistagen’S Investigational Menopausal Hot Flash Therapy, Ph80 Nasal Spray, In Japan
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Table: Fuji Pharmaceutical - 9-MTH group results
Table: Fuji Pharmaceutical - 6-MTH group results
Table: Fuji Pharmaceutical -Q1 group results
Alvotech up on extended biosimilar development pact with Japan's Fuji Pharma
Brief: Alvotech Says Co And Fuji Pharma Expand Partnership Adding A New Biosimilar Candidate
Table: Fuji Pharmaceutical -2021/22 group results
Table: Fuji Pharmaceutical -2021/22 parent results
Table: Fuji Pharmaceutical -2021/22 group forecast
Table: Fuji Pharmaceutical -2021/22 parent forecast
Table: Fuji Pharmaceutical -2021/22 div forecast
Alvotech up on partner's application for biosimilar candidate's approval